Tables of Rules

INTEGRASE STRAND TRANSFER INHIBITORS

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

Attachment inhibitor Integrase strand transfer inhibitors

HIV - 2    

  Mutations associated with resistance Mutations associated with "possible resistance"
RAL

T66K [10]
E92Q [1, 2]
G118R [10,17]
F121Y [10,17]
G140A/S [7]
Y143A/C/G/H/R/S [1, 3, 4, 5, 8, 14]
Q148E/G/H/K/R [1, 2]
V151L [9]
N155H/S/T [1, 2, 9]
E157Q [2]
S230R [18, 33, 34, 35]
R263K [16,18]
L74F + V75I [38]

 
EVG T66I/A/K [6]
E92Q [6]
T97A [21, 22]
G118R [17]
F121Y [9,17]
E138K
G140C/S
Y143A/C/G/H/R/S [14]
P145S [9]
S147G [21]
Q148H/R/K [6]
V151L [9]
N155H/S/T [6, 9]
E157Q [11,37]
S230R [18, 33, 34, 35]
R263K [18]
L74F + V75I [38]

DTG* 50 mg BID










50 mg QD

G118R [12,13]
F121Y [17]
V151L [9,25]
S153F/Y [9, 25,28, 36]
T66K + L74M [9]
E92Q + N155H [9, 23, 24]
Q148H/K/R + at least 2 mutations among: L74I or E138A/K/T or G140A/C/S [15]
Q148H/K/R + N155H [9,29,30]
R263K [16]


G118R [12,13]
F121Y [17]
E138A/K/T [15]
puce G140A/C/S [15]
puce Q148H/K/R [15]
puce V151L [9,25]
S153F/Y [9,25,28, 36]
puce N155H [18]
puce S230R [31]
puce R263K [16]
puce T66K + L74M [9]
puce L74I + E92Q [32]

T66K [9]
Q148H/K/R + 1 mutation among: L74I or E138A/K/T or G140A/C/S [15]









puce T66K [9]
puce E157Q [19, 20, 37]
CAB* G118R [12,13]
F121Y [17]
E138A/K/T [15]
puce G140A/C/S [15]
puce Q148H/K/R [15]
puce V151L [9,25]
S153F/Y [9,25,28, 36]
puce N155H [18]
puce S230R [31]
puce R263K [16]
puce T66K + L74M [9]
puce L74I + E92Q [32]
puce T66K [9]
puce E157Q [19, 20, 37]
BIC** G118R [12,13]
F121Y [17]
E138A/K/T
puce G140A/C/S
puce Q148H/K/R
puce V151L [9,25]
S153F/Y [9,25,28, 36]
puce N155H [18]
puce S230R [31]
puce R263K [16]
puce T66K + L74M [9]
puce L74I + E92Q [32]
puce T66K [9]
puce E157Q [19, 20, 37]


RAL: raltegravir, EVG: elvitegravir, DTG: dolutegravir, CAB: cabotegravir, BIC: bictegravir.
* Please note that rules are different for DTG 50 mg BID and 50 mg QD.
**Due to few data and to the very close structures of dolutegravir and cabotegravir and bictegravir rules for dolutegravir QD are transposed to cabotegravir and bictegravir.

For DNA provirus, impact of stop codons and G->A mutations on ARV resistance is unknown

References